// Biotech and Pharma Therapeutics
5 topics to watch as MDUFA negotiations restart
January 14, 2026 / MDUFA VI / FDA medical devices / user fee negotiations / medtech funding / healthcare regulation
FDA and medtech industry negotiations for MDUFA VI are progressing rapidly, with potential Congressional submission in 2026. Key concerns include funding, safety, transparency, and FDA staffing capacity following recent cuts.
Mobile Engagement in Healthcare: A Foundational Element for Building Brand Loyalty
January 14, 2026 / mobile health engagement / patient loyalty strategy / digital health experience / healthcare mobile apps / personalized care delivery
A unified, personalized mobile strategy is crucial for U.S. health systems to improve patient engagement, drive service conversion, and build brand loyalty—especially as consumer expectations rise and trust in healthcare systems declines.
Millions with dementia still prescribed drugs linked to falls and confusion
January 13, 2026 / dementia medication safety / high-risk prescriptions / cognitive impairment drugs / fall risk dementia / inappropriate prescribing elderly
Dementia patients are still frequently prescribed high-risk brain-altering drugs, despite safety guidelines, increasing their risk of falls and confusion—often without clear medical justification, raising concerns about medication safety in cognitive care.
Industry reacts to proposed health IT certification deregulation
January 13, 2026 / health IT certification / EHR interoperability rules / autonomous AI healthcare / information blocking reform / healthcare data security
Proposed HTI-5 changes aim to simplify health IT certification, integrate autonomous AI, and clarify information blocking rules, but industry leaders warn of increased operational burdens and unclear security expectations for providers and developers.
Key questions need answering when deploying ambient scribes
January 13, 2026 / ambient AI scribes / clinical documentation tools / healthcare AI governance / patient data privacy / digital health workflow
Ambient AI scribes offer clinical potential but raise unresolved issues around workflow integration, patient consent, privacy, and true ROI. Effective governance and stakeholder alignment are critical to realizing their benefits in real-world healthcare environments.
// 4th Industrial Revolution
AI casts long shadow across Tuesday’s venture deals
January 13, 2026 / AI drug discovery / protein interaction therapeutics / PROTAC biotechnology / generative AI biotech / molecular glue platforms
AI-driven biotech companies raised nearly $190 million during JPM Day 2, with Proxima securing $80 million to advance generative AI platforms for proteome-scale drug discovery, including molecular glues and PROTACs targeting complex protein interactions.
Fullscript and ŌURA Collaborate to Bring Wearable Data Into Clinical Workflows
January 13, 2026 / wearable health integration / digital biometrics clinical / Oura Ring healthcare / personalized care data / remote patient monitoring
Fullscript and ŌURA are integrating wearable biometric data into clinical workflows, enabling providers to access sleep, activity, and recovery insights alongside diagnostics to deliver more personalized, proactive care. The partnership launches in early 2026.
46% of U.S. counties don’t have a cardiologist. ARPA-H’s new agentic AI program could bring them specialized care
January 13, 2025 / cardiology access gap / agentic AI healthcare / rural heart disease / ARPA-H ADVOCATE program / autonomous specialty care
ARPA-H’s new ADVOCATE program aims to address the critical cardiology access gap—46% of U.S. counties lack a cardiologist—by developing FDA-authorized agentic AI systems to autonomously deliver advanced cardiovascular care, especially in underserved rural areas.
Hippocratic AI Consolidates Life Sciences Leadership with Acquisition of Grove AI and Key Executive Appointments [release]
January 13, 2025 / generative AI healthcare / life sciences innovation / AI clinical trials / patient engagement AI / Grove AI acquisition
Hippocratic AI has acquired Grove AI and expanded its leadership to accelerate safe, scalable generative AI adoption across life sciences, enhancing patient engagement, clinical trials, and R&D workflows with regulatory-aligned AI agents and strategic support from Boston Consulting Group.
Medtronic gets FDA clearance for smart insulin pen app
January 13, 2026 / smart insulin pen / diabetes management app / Medtronic FDA clearance / glucose sensor integration / MiniMed Go features
Medtronic’s MiniMed Go app has received FDA 510(k) clearance, enabling integration with Abbott’s glucose sensor. The app supports smart insulin pen users with dose tracking, missed dose alerts, and clinical reporting to improve diabetes management.
// Business & Markets
JPM26: BioNTech gears up for multiproduct oncology status by 2030
January 14, 2026 / BioNTech oncology pipeline / mRNA cancer therapy / ADC cancer drugs / PD-L1 VEGF antibody / Covid-19 to oncology pivot
BioNTech is transitioning from Covid-19 vaccines to oncology, aiming for multiple commercial cancer drugs by 2030. With over 25 late-stage programs, including ADCs, mRNA immunotherapies, and bispecific antibodies, the company is positioning itself as a multiproduct oncology leader.
Caldera Therapeutics debuts with $112.5 million
January 14, 2026 / Caldera Therapeutics launch / bispecific antibody IBD / CLD-423 Phase I / IL-23p19 TL1A targets / inflammatory bowel disease therapy
Caldera Therapeutics launched with $112.5M to advance CLD-423, a first-in-class bispecific antibody targeting IL-23p19 and TL1A for IBD and other inflammatory diseases, now in Phase I trials following a major licensing deal with Qyuns Therapeutics.
Smith & Nephew to acquire Integrity Orthopaedics for up to $450M
January 14, 2025 / Smith & Nephew acquisition / rotator cuff repair / shoulder surgery innovation / orthopedic device market / Integrity Orthopaedics deal
Smith & Nephew will acquire Integrity Orthopaedics for up to $450M to enhance its rotator cuff repair (RCR) portfolio, aiming to reduce re-tear rates and improve outcomes in the growing $875M shoulder repair market.
Lilly and Novo Nordisk oral obesity drugs take top billing at JP Morgan
January 14, 2026 / oral obesity drugs / GLP-1 agonists / Lilly orforglipron launch / Novo oral Wegovy / obesity treatment market
At JPM 2026, Eli Lilly and Novo Nordisk highlighted their oral obesity drug launches—Lilly’s orforglipron and Novo’s oral Wegovy—as both companies expand their GLP-1 portfolios to capture broader market share in the competitive obesity treatment landscape.
Converge Bio Lands $25M to Replace Trial-and-Error Drug Discovery
January 13, 2026 / AI drug discovery / antibody optimization AI / protein manufacturing yield / biomarker identification platform / Converge Bio funding
Converge Bio raised $25M to scale its end-to-end AI platform, designed to replace trial-and-error drug discovery with validated, no-code systems that improve antibody design, protein manufacturing, and biomarker identification across oncology, autoimmune, and neurodegenerative diseases.
// Legal & Regulatory
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
January 13, 2026 / FDA post-approval changes / biologics manufacturing regulation / pharmaceutical reshoring USA / SUPAC modernization request / drug supply chain reform
AbbVie, Amgen, and Eli Lilly are urging the FDA to modernize post-approval change regulations, particularly for biologics, to reduce barriers to U.S. pharmaceutical manufacturing, accelerate site transfers, and support drug supply chain resilience and innovation.
Boston Scientific gains FDA’s OK for new PFA catheter
January 14, 2026 / pulsed field ablation / atrial fibrillation treatment / Farapoint catheter FDA / cardiac ablation device / Boston Scientific approval
Boston Scientific’s Farapoint pulsed field ablation catheter has received FDA approval for adjunctive use in treating persistent atrial fibrillation, offering precise lesion delivery while preserving cardiac tissue and showing strong safety and efficacy in preventing atrial flutter recurrence.
Atara receives FDA complete response letter for Ebvallo BLA application
January 13, 2026 / Ebvallo FDA CRL / EBV+ PTLD therapy / Atara BLA rejection / single-arm trial concerns / tabelecleucel approval setback
Atara received an FDA complete response letter for Ebvallo’s BLA, citing concerns over the single-arm ALLELE trial’s adequacy despite prior alignment. No safety issues remain, but the agency now deems the data insufficient for accelerated approval of EBV+ PTLD treatment.
FDA delays decision on Travere’s Filspari in key kidney disease indication
January 14, 2025 / Filspari FDA delay / FSGS drug approval / Travere Therapeutics FSGS / kidney disease treatment / proteinuria reduction therapy
The FDA delayed its decision on Travere’s Filspari for FSGS by three months, citing the need for clinical benefit clarification. While safety isn’t in question, the delay impacts market expectations for what could be the first approved FSGS therapy.
How To Navigate The EU’s Changing Legal Landscape For Pharma In 2026
January 14, 2026 / EU pharma regulations / Biotech Act 2026 / Critical Medicines Act / pharmaceutical policy Europe / drug supply chain reform
The EU is advancing significant 2026 regulatory reforms, including updates to the pharma package, a new Biotech Act, and the Critical Medicines Act, all aimed at reshaping pharmaceutical innovation, access, and supply chain resilience across Europe.
// Research & Development
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data
January 14, 2026 / MariTide weight loss / GLP-1 GIPR agonist / type 2 diabetes therapy / Amgen obesity drug / monthly T2D treatment
Amgen’s MariTide showed strong Phase II efficacy for obesity and type 2 diabetes, with significant HbA1c and weight reductions. The GLP-1/GIPR agonist demonstrated promise as a potential once-monthly or quarterly maintenance therapy for chronic metabolic conditions.
Scientists finally uncover why statins cause muscle pain
January 14, 2026 / statin muscle pain / calcium leak discovery / cholesterol drug side effects / statin-induced weakness / muscle cell damage
Researchers have discovered that certain statins bind to a key muscle protein, causing harmful calcium leaks in muscle cells, which may directly weaken muscles or trigger their breakdown—shedding light on the root cause of statin-induced muscle pain.
New BIND screener identifies brain-related comorbidities risk in Duchenne muscular dystrophy
January 14, 2025 / Duchenne muscular dystrophy / BIND screener tool / neurodevelopmental comorbidities risk / ADHD anxiety screening / cognitive assessment DMD
Researchers developed and validated the BIND screener, a questionnaire-based tool to identify Duchenne muscular dystrophy patients at risk for brain-related comorbidities like ADHD, anxiety, and language disorders, demonstrating strong accuracy across international populations.
Massive brain study reveals why memory loss can suddenly speed up with age
January 14, 2025 / age-related memory loss / brain tissue shrinkage / hippocampus cognitive decline / MRI brain aging / memory decline research
A large international study found that age-related memory loss accelerates due to widespread brain tissue shrinkage, not just hippocampal decline. Multiple brain regions contribute to this cumulative vulnerability, explaining the sudden worsening of memory in later life.
Doctors discover the source of mysterious intoxication
January 13, 2025 / auto-brewery syndrome / gut microbiome alcohol / endogenous ethanol production / fecal microbiota transplant / unexplained intoxication condition
Researchers identified specific gut microbes and metabolic pathways responsible for auto-brewery syndrome, where endogenous alcohol production causes intoxication. Patient samples produced excess ethanol, and fecal microbiota transplantation showed sustained symptom improvement in a reported case.
// Politics
Kennedy adds two OB-GYNs to vaccine advisory panel amid review of shots for pregnant women
January 13, 2026 / pregnancy vaccine safety / OB-GYN advisory panel / maternal immunization review / Covid vaccine pregnancy / vaccine policy oversight
New OB-GYN appointments to a vaccine advisory panel come as recommendations for vaccination during pregnancy are reviewed, raising concerns among experts due to prior public questioning of vaccine safety despite strong evidence supporting maternal immunization benefits.
Cyber breach hit NZ’s largest NZ medical oncology provider
January 14, 2026 / healthcare cyber breach / oncology data security / Canopy Healthcare hack / patient data protection / New Zealand medical cybersecurity
Canopy Healthcare, New Zealand’s largest private oncology provider, reported a cyber breach affecting administrative systems but not patient records or clinical services. A forensic investigation is ongoing, with authorities notified and legal protections enacted to prevent data misuse.
New law mandates Singaporean providers to share patient data
January 14, 2026 / Singapore health data law / National Electronic Health Record / patient data sharing / healthcare privacy safeguards / coordinated care legislation
Singapore’s new Health Information Bill mandates all healthcare providers to contribute patient data to the National Electronic Health Record by 2027, aiming to improve care coordination, enhance safety, and enable public health research while enforcing strict privacy safeguards.
Russia to focus on more active import substitution in domestic pharma sector
January 14, 2026 / Russia pharma strategy / drug import substitution / domestic drug production / essential medicines localization / healthcare policy 2030
Russia’s new healthcare strategy through 2030 prioritizes pharmaceutical import substitution, aiming to increase domestically produced drugs to 90% overall and within the essential medicines list, to strengthen national drug supply and reduce reliance on foreign products.
India’s pharma footprint in Iran faces new US pressure
January 14, 2026 / India Iran pharma trade / US tariff pressure / pharmaceutical export growth / Iran drug market / geopolitical impact healthcare
India’s pharmaceutical exports to Iran surged 70% in 2025, but new U.S. tariff threats on countries trading with Iran could disrupt this growth, adding geopolitical pressure to India’s expanding pharma footprint in the region.